In discovery they would take over Adam's finances and find his connections to the shorts.

I believe Adam will be sued after TLD for trade libel.

If you can't manage your credit cards you should not be buying stock.

Selling stock to pay credit card bills?

Maybe you do that but not I.

NWBO will not sell the MicroDEN.

By being the first time enter the market they have this advantage.

Being able to produce more cheaper provides them an advantage against any competitors which were to release a DC vaccine that doesn't violate their patent.

By being first to market and lowest cost producer they would be in a position to buy out any competing technology.

This is how NWBO becomes a BP.

This is why a Phase 1 nature paper which shows vaccines killing IDH gliomas isn't of concern. That's simple future additions to the NWBO pipeline.

Freezing tumors makes sense so others can validate portions of the trial should that be needed.

With these tumor samples it would be trivial to sequence them then see which patients expressed IDH.

The paper validates that IDH is a target worth hitting though we know that IDH isn't in every tumor.

Can you tell us how the firm are able to identify IDH mutation after the trial even though this was not gathered when it began?

Do they have frozen pieces of tumor from patients?

They're not going to sell FlaskWorks to anyone. This is their golden goose.

Advent will operate the MicroDEN. That's what they do. The equipment is owned by NWBO. Advent uses it to crank out DCVax.

IDH Glioma Nature paper more relevant.

https://www.nature.com/articles/s41586-021-03363-z

If rates go up we will be paying more on interest for our debt than the entire defense budget. That isn't sustainable.

The last time the Fed flirted with raising rates in December 2019 the markets took a sharp dive.

National debt makes raising rates impossible.

You said you believed in Les' claim.

You do realize that Jane Street are one of the most sophisticated market markers?

By law all market makers are bound to execute the best price for any trade.

They're also required to retain a history of their trades as well as the bid and ask at all other points on the market.

The idea that there's been manipulation for like a decade seems to not make much sense considering these firms are required by law to retain evidence of said manipulation.

NWBO simply doesn't have enough buyers because it's an OTC penny stock which gets no coverage. That will soon change with TLD and approval.

First we have some guy claiming Linda pushed put the Phase 5 report. Now you're saying Les wants to wait until Covid is over. These are both crazy ideas.

Loose lips sink ships. If we spread every crazy thing Les said you would call us the BigBiz Show. We are not.

Vaccines have been around since before we all were born. The only people who don't believe in them are crazy. Who cares about their opinion? They are not working at the FDA.

NWBO are applying for MHRA approval. Their material will not include "we now know how vaccines work thanks to Covid."

Any sane person would have never chosen the path NWBO took. You have to be on hallucinogens to think LP planned it all

Delta8 must be powerful!

As Buffet says you're not buying a stock but a company. Keep it for at least 5 years or don't buy at all. This will be challenging when NWBO hits $30 then $50.

Well said good sir!

I will gladly delete this app after TLD.

FOUR COMMAS!

I never learned to read!

By then I'll be in Nice looking out on the bay not really caring about these arguments.

Cognate has not split with NWBO you crackpot. They mention the trial on their website as well as within the TN PILOTS application.

Did the knowledge and equipment used to make DCVax just disappear after they made the final DCVax-L trial vaccine?

AngryLibrarian will never be happy.

Yes, NWBO could be the first pharmaceutical firm to reach the 3 comma club.

You will never understand basic math. Please go run for Senate in Alabama.

Merck doesn't have a new oncology platform that's applicable to all solid tumors. They have checkpoint inhibitors which are failing to produce results.

Reverse split requires shareholder approval. We would vote against as it makes zero sense to reduce the number of shares. Fully diluted we are still looking at 30 dollars a share upon DCVax-L approval on GBM indication alone. Easily $100+ with other cancers.

Anyone talking about reverse split wants to scare longs into selling.

They know topline. They wouldn't apply for UK approval with bad data.

FlaskWorks requires FDA approval through a bridging study to show it can produce DCVax the same way CRL can do with their clean rooms. Likely they will do that study after DCVax gets approval with current process.

Diamond hands then we up millions.

After reading more about CYDY endpoint failure, and their attempt at post hoc analysis, I do think investors are owed an explanation as to why we have this ongoing delay. Are NWBO doing the same cherrypicking or are they pursuing a path toward actual approval? The interim blinded data, and fact that endpoints were changed by regulatory agencies, suggests we are on a good path since the firm has remained above board. Though it's unseemly to see a prominent proponent of DCVax, who has a paper pinned to the top of this board, continue to defend a failed trial when the facts are not in dispute.

Does anyone have any more details into the trial design, IDMC, SAP, regulatory endpoint changes, and how these mean that we as shareholders are less likely to suffer the same fate as CYDY's failed trial? I am sure these have been stated already.

Thank you.

Roll Tide!

Here's one

ublication-of-results-from-its-phase-3-confirm-study-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1-301240196.html

Has another CEO conducted an oncology trial for this long?

They could be shorts. They could also be trolls who are invested in this board after being crank skeptics for over a decade.

Quickest way to help patients would be JV that shares profit with a BP which helps distribute DCVax and subsidize other indications. I at first was for NWBO going it alone but they're already having issues with execution.

This guy is responsible for quality control ensuing DCVax made to UK regulatory standards.

Restating the work you and others have done which I have kept straight in my mind during this time of volatility.

We are 1st and goal. No need go 28-3! Stay steady everyone and ignore the short tolls!

Again Cognate mentioned two firms in their TN PILOTS application. One was Northwest. They mentioned a clinical trial on their website? Guess which phase III GBM trial at 80 plus sites they're referencing?

Linda built up Cognate so it can manufacture DCVax. The high cost to make Provenge was one reason it was never available for patients. Cognate achieved its goal. Now it was bought by a much larger firm which can continue that process at greater scale. We also have Advent for the UK market which has hired new staff who state they're making DCVax.

We also have new patients being enrolled in DCVax and Keytruda combination studies. NWBO smartly delegated UCLA for this study so they can focus on finishing the DCVax-L phase III. Do you think all of this many pieces would happen if the trial failed? In fact all indicators show the opposite of your conspiracy laden theories.

Maybe it was actually successful but that information isn't publicly know yet